Identification and Profiling of a Selective and Brain Penetrant Radioligand for in Vivo Target Occupancy Measurement of Casein Kinase 1 (CK1) Inhibitors
- ACS Chem Neurosci. 2017 Sep 20;8(9):1995-2004. doi: 10.1021/acschemneuro.7b00155.
- 1. Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development , 1 Portland, Cambridge, Massachusetts 02139, United States.
- 2. Worldwide Medicinal Chemistry, Pfizer Worldwide Research and Development , 558 Eastern Point Rd, Groton, Connecticut 06340, United States.
- 3. Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development , 558 Eastern Point Rd, Groton, Connecticut 06340, United States.
- 4. Internal Medicine Research Unit, Pfizer Worldwide Research and Development , 1 Portland, Cambridge, Massachusetts 02139, United States.
- 5. Chemical Research and Development, Pharmaceutical Sciences, Pfizer Worldwide Research and Development , 558 Eastern Point Rd, Groton, Connecticut 06340, United States.
To enable the clinical development of our CNS Casein Kinase 1 delta/epsilon (CK1δ/ε) inhibitor project, we investigated the possibility of developing a CNS positron emission tomography (PET) radioligand. For this effort, we focused our design and synthesis efforts on the initial CK1δ/ε inhibitor HTS hits with the goal of identifying a compound that would fulfill a set of recommended PET ligand criteria. We identified [3H]PF-5236216 (9) as a tool ligand that meets most of the key CNS PET attributes including high CNS MPO PET desirability score and kinase selectivity, CNS penetration, and low nonspecific binding. We further used [3H]-9 to determine the binding affinity for PF-670462, a literature CK1δ/ε inhibitor tool compound. Lastly, [3H]-9 was used to measure in vivo target occupancy (TO) of PF-670462 in mouse and correlated TO with CK1δ/ε in vivo pharmacology (circadian rhythm modulation).
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Casein KinaseResearch Areas: Neurological Disease